Your browser doesn't support javascript.
loading
Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.
Clark, Richard E; Basabrain, Ammar A; Austin, Gemma M; Holcroft, Alison K; Loaiza, Sandra; Apperley, Jane F; Law, Christopher; Scott, Laura; Parry, Alexandra D; Bonnett, Laura; Lucas, Claire M.
Afiliação
  • Clark RE; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK.
  • Basabrain AA; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK.
  • Austin GM; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK.
  • Holcroft AK; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK.
  • Loaiza S; John Goldman Centre for Cellular Therapy, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK.
  • Apperley JF; Centre for Haematology, Imperial College London at Hammersmith Hospital, London W12 0HS, UK.
  • Law C; Technology Directorate, University of Liverpool, Liverpool L69 3GA, UK.
  • Scott L; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK.
  • Parry AD; Chester Medical School, University of Chester, Bache Hall, Chester CH2 1BR, UK.
  • Bonnett L; Department of Biostatistics, University of Liverpool, Liverpool L69 3GA, UK.
  • Lucas CM; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK.
Cancers (Basel) ; 13(9)2021 Apr 29.
Article em En | MEDLINE | ID: mdl-33947031

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article